Drug overdose deaths in the United States have fallen for the third consecutive year since the 2022 peak, with provisional CDC data released June 17, 2026, projecting approximately 69,147 deaths for the 12 months ending in January 2026, a 13.2% decline from the prior year. That is the equivalent of roughly 10,000 fewer Americans dying from overdoses compared to the year before, and it represents the clearest evidence to date that the tools developed to address this crisis, including naloxone expansion, treatment access programs, and public health surveillance, can measurably reduce death rates even against a lethal fentanyl supply.
But public health analysts are sounding a cautionary note alongside the data. The conditions that produced this decline are now under direct pressure: Medicaid coverage is being narrowed, federal overdose prevention program budgets are being reduced, and enforcement-only policy frameworks are gaining ground in states where harm reduction programs have been most effective. At 69,147 projected deaths, which amounts to roughly 190 Americans dying from overdoses every day, the scale of the crisis demands both an honest accounting of what is working and a clear-eyed assessment of what could stop working.
